Logo image of MREO

MEREO BIOPHARMA GROUP PL-ADR (MREO) Stock Fundamental Analysis

NASDAQ:MREO - Nasdaq - US5894921072 - ADR - Currency: USD

2.61  +0.11 (+4.4%)

After market: 2.63 +0.02 (+0.77%)

Fundamental Rating

3

Overall MREO gets a fundamental rating of 3 out of 10. We evaluated MREO against 566 industry peers in the Biotechnology industry. MREO has a great financial health rating, but its profitability evaluates not so good. MREO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MREO had negative earnings in the past year.
In the past year MREO has reported a negative cash flow from operations.
MREO had negative earnings in 4 of the past 5 years.
MREO had a negative operating cash flow in each of the past 5 years.
MREO Yearly Net Income VS EBIT VS OCF VS FCFMREO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -56.62%, MREO perfoms like the industry average, outperforming 42.40% of the companies in the same industry.
MREO's Return On Equity of -70.94% is in line compared to the rest of the industry. MREO outperforms 56.36% of its industry peers.
Industry RankSector Rank
ROA -56.62%
ROE -70.94%
ROIC N/A
ROA(3y)-46.82%
ROA(5y)-74.73%
ROE(3y)-61.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MREO Yearly ROA, ROE, ROICMREO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MREO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MREO Yearly Profit, Operating, Gross MarginsMREO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

7

2. Health

2.1 Basic Checks

MREO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MREO has more shares outstanding
Compared to 5 years ago, MREO has more shares outstanding
Compared to 1 year ago, MREO has a worse debt to assets ratio.
MREO Yearly Shares OutstandingMREO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
MREO Yearly Total Debt VS Total AssetsMREO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

MREO has an Altman-Z score of 6.57. This indicates that MREO is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.57, MREO belongs to the top of the industry, outperforming 83.57% of the companies in the same industry.
MREO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.57
ROIC/WACCN/A
WACC9.23%
MREO Yearly LT Debt VS Equity VS FCFMREO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 5.40 indicates that MREO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.40, MREO is in line with its industry, outperforming 58.83% of the companies in the same industry.
A Quick Ratio of 5.40 indicates that MREO has no problem at all paying its short term obligations.
With a Quick ratio value of 5.40, MREO perfoms like the industry average, outperforming 59.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.4
Quick Ratio 5.4
MREO Yearly Current Assets VS Current LiabilitesMREO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for MREO have decreased strongly by -50.00% in the last year.
The Revenue for MREO has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 43.46% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-5.92%
EPS Next 2Y26.87%
EPS Next 3Y13.32%
EPS Next 5Y43.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MREO Yearly Revenue VS EstimatesMREO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2023 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
MREO Yearly EPS VS EstimatesMREO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.2 -0.2 0.4 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MREO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MREO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MREO Price Earnings VS Forward Price EarningsMREO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MREO Per share dataMREO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

A more expensive valuation may be justified as MREO's earnings are expected to grow with 13.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.87%
EPS Next 3Y13.32%

More info and screens

0

5. Dividend

5.1 Amount

MREO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEREO BIOPHARMA GROUP PL-ADR

NASDAQ:MREO (4/28/2025, 8:25:48 PM)

After market: 2.63 +0.02 (+0.77%)

2.61

+0.11 (+4.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26 2025-03-26/bmo
Earnings (Next)N/A N/A
Inst Owners70.36%
Inst Owner Change0.01%
Ins Owners0.87%
Ins Owner Change0%
Market Cap414.99M
Analysts88
Price Target7.48 (186.59%)
Short Float %22.22%
Short Ratio3.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-336.32%
Min EPS beat(2)-449.62%
Max EPS beat(2)-223.03%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)5.47%
EPS NQ rev (1m)-149.33%
EPS NQ rev (3m)-2850.52%
EPS NY rev (1m)69.6%
EPS NY rev (3m)76.45%
Revenue NQ rev (1m)-33.33%
Revenue NQ rev (3m)120.39%
Revenue NY rev (1m)8.78%
Revenue NY rev (3m)84.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.81
P/tB 6.88
EV/EBITDA N/A
EPS(TTM)-0.29
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS0.38
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.62%
ROE -70.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.82%
ROA(5y)-74.73%
ROE(3y)-61.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.25%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.4
Quick Ratio 5.4
Altman-Z 6.57
F-Score2
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)35.04%
Cap/Depr(5y)37.89%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y-5.92%
EPS Next 2Y26.87%
EPS Next 3Y13.32%
EPS Next 5Y43.46%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-66.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.25%
EBIT Next 3Y19.68%
EBIT Next 5YN/A
FCF growth 1Y-55.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.38%
OCF growth 3YN/A
OCF growth 5YN/A